Titlebook: Nucleic Acid Therapeutics in Cancer; Alan M. Gewirtz Book 2004 Springer Science+Business Media New York 2004 DNA.cancer.tumor.tumor growth

有角

Lida K. Gifford PhD,Ponzy Lu PhD,Alan M. Gewirtz MD by the Professors Cerf, Lyons and Slade. We have decided to publish these courses separately. This volume contains the course of Professor Cerf. We cordially thank the author for his performance at the summer school, and for the redaction of these notes. 69 participants have attended this school. 3

元音

Free-Radical

Consensus

頂點

Antisense Methodology) complementary to a region of an mRNA to form a complex should prevent the ribosome from traveling along the message and thus prevent translation . . Now, with 25 years of experience, we realize that we have overlooked a fair number of problems associated with this strategy. However, this time has

Alienated

ventilate

Targeted Genome Modification Via Triple Helix Formationr progression of different diseases. This research has led to new and innovative therapies in the treatment of disease. Traditionally, most active drugs are inhibitors of proteins. However, in recent years synthetic oligonucleotides have been developed as a means to rationally design therapeutic age

RECUR

Therapeutic Applications of Ribozymesr forming covalent bonds with extraordinary specificity, accelerating the rate of these reactions. The ability of RNA to serve as a catalyst was first shown for the self-splicing Group I intron of . and the RNA moiety of RNase P .. Subsequent to the discovery of these two RNA enzymes, RNA-mediated c

verdict

顯示

Targeted Destruction of Small, Stable RNAsnucleotides (ONs) were originally used to destroy mRNAs in order to reveal the function of specific proteins, their use has logically been extended to therapy for diseases that result from the unwanted expression of specific proteins, as in cancer. However, choosing the ON to target mRNAs in these c